Drugs that selectively induce apoptosis of senescent cells may be effective candidates for the treatment of fibrodysplasia ossificans progressiva (FOP) flare-ups via the inhibition of tissue reprogramming and subsequent prevention of endochondral heterotopic ossification (HO), preclinical study findings indicate.

The prevalence of fibrodysplasia ossificans progressiva (FOP) in the US is higher than previously believed, according to research published in the Orphanet Journal of Rare Diseases.

Children treated for fibrodysplasia ossificans progressiva (FOP) with imatinib in an off-on-off-on (O4) regimen have fewer flare-ups, decreased swelling, and improved function when on versus off treatment, US researchers report.

Experimental data suggest that the tyrosine kinase inhibitor saracatinib may be a candidate for the treatment of fibrodysplasia ossificans progressiva (FOP), via its inhibition of activin receptor-like kinase (ALK)2.

A detailed analysis of radiographs from individuals with ACVR1R206H -mutated fibrodysplasia ossificans progressiva (FOP) has found that great toe malformations result from monophalangeal and biphalangeal phenotypes.

Results of two trials presented at the ASBMR 2020 Annual Meeting Virtual Event show promising new options for the treatment of fibrodysplasia ossificans progressiva (FOP).

Patients with fibrodysplasia ossificans progressiva (FOP) wait an average of 1.5 years to receive a correct diagnosis, with more than half initially misdiagnosed, show data from the international FOP registry.